Cibus, Inc. Reports Director Changes and Compensation Updates
Ticker: CBUS · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1705843
| Field | Detail |
|---|---|
| Company | Cibus, Inc. (CBUS) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
TL;DR
Cibus board shakeup and exec pay changes filed. Watch closely.
AI Summary
Cibus, Inc. filed an 8-K on November 18, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing indicates a departure of directors and the election of new ones, alongside updates to compensatory arrangements for certain officers. This is a routine filing to update the SEC on corporate governance and executive compensation matters.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, which are important for investors to monitor.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not present immediate financial or operational risks.
Key Numbers
- 001-38161 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-1967997 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cibus, Inc. (company) — Registrant
- November 18, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, CA (location) — Principal Executive Offices
- Calyxt, Inc. (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates a departure of directors and the election of new directors, but the specific names of departing and newly elected directors are not detailed in this summary section of the 8-K.
What are the key updates regarding compensatory arrangements?
The filing states there are updates to compensatory arrangements of certain officers, but the specifics of these arrangements are not provided in this initial summary.
When was this report filed with the SEC?
The report was filed on November 18, 2024.
What is the former name of Cibus, Inc.?
The former name of Cibus, Inc. was Calyxt, Inc., with a name change date of May 4, 2017.
Where are Cibus, Inc.'s principal executive offices located?
The principal executive offices of Cibus, Inc. are located at 6455 Nancy Ridge Drive, San Diego, CA 92121.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-11-18 17:02:23
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share CBUS The NASDAQ Sto
Filing Documents
- cbus-20241118.htm (8-K) — 25KB
- 0001628280-24-048288.txt ( ) — 145KB
- cbus-20241118.xsd (EX-101.SCH) — 2KB
- cbus-20241118_lab.xml (EX-101.LAB) — 21KB
- cbus-20241118_pre.xml (EX-101.PRE) — 12KB
- cbus-20241118_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 18, 2024, the Board of Directors (the "Board") of Cibus, Inc. (the "Company") appointed August Moretti to serve as a member of the Board, effective as of such date. Mr. Moretti will also serve as a member of the Board's Audit Committee, effective as of such date. Mr. Moretti, 74, has extensive operating and financial executive experience in all phases of company growth and funding, from early-stage development to product approval and commercialization. Mr. Moretti is currently self-employed as a consultant. From 2019 until his retirement in September 2023, Mr. Moretti served as the Chief Financial Officer of 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company. Mr. Moretti previously served as Chief Financial Officer at Assertio Therapeutics (formerly Depomed, Inc.), a specialty pharmaceuticals company focused in pain and neurology, from January 2012 until August 2018. Prior to this, Mr. Moretti served as Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc., a pharmaceutical company, and as Chief Financial Officer and General Counsel of Alavita, Inc., a personalized medicine company. Earlier in his career, Mr. Moretti was a partner in an international law firm, where his practice included representation of life science companies on issues relating to public and private financings, mergers and acquisitions, corporate governance, disclosure and public reporting. Mr. Moretti received his B.A. in Economics from Princeton University in 1972. He received his J.D. from Harvard Law School in 1975. There are no arrangements or understandings between Mr. Moretti and any other persons pursuant to which Mr. Moretti was named as a director of the Board. Mr. Moretti has no direct or indirect material interest in any transaction or proposed transaction required
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Cibus, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 18, 2024 CIBUS, INC. By: /s/ Rory Riggs Name: Rory Riggs Title: Chief Executive Officer and Chairman